Our Approach
Opportunity Pharma is an early-stage software-as-a-service (SaaS) business, based in the UK.
Built on proprietary AI (Artificial Intelligence), our innovation holds significant data on diseases, biological targets, and drug-like molecules. The AI gathers information for normalisation while learning and orchestrating tasks on behalf of the user. What’s more, our AI has the power to evaluate thousands of opportunities for hundreds of diseases, which investors can use with ease.
Utilising AI for drug discovery
Existing solutions tend to be expensive, slow and difficult to manage, especially given the shortage of executives.
At Opportunity Pharma, we transform opportunity delivery by offering curated and objective comparisons of new medicine opportunities for:
Life Science Investors
Small-Medium Sized Enterprises
Pharma Organisations
Research Organisations
Life Science Investors
Small-Medium Sized Enterprises
Pharma Organisations
Research Organisations
Importantly, investors require a constant supply of de-risked and investable drug opportunities before committing significant funds to their development projects. That’s why our AI drives tasks to satisfy pre-defined drug programme goals, to help investors underpin key decisions, especially as reliable data is in short supply, with limited time for analysis.
By using the immense power of AI, we orchestrate tasks on behalf of our clients without intervention, ensuring opportunities for investors are de-risked. Whether clients are looking for opportunities for specific diseases, biological targets, or drug discovery and development, our AI solution can seek the investable opportunities required.
Discover the power of proprietary AI
To find out more about Opportunity Pharma and our partnering opportunities, please get in touch.